The post VIRTUAL: THESE levels hint at a potential reversal ahead appeared on BitcoinEthereumNews.com. Prices in the crypto arena dropped sharply as the market The post VIRTUAL: THESE levels hint at a potential reversal ahead appeared on BitcoinEthereumNews.com. Prices in the crypto arena dropped sharply as the market

VIRTUAL: THESE levels hint at a potential reversal ahead

Prices in the crypto arena dropped sharply as the market took a hit due to the current global geopolitical unrest and policy. Inasmuch, Virtual Protocol’s [VIRTUAL] price shrunk by 11% recently.

At press time, the price move had pushed the token into a critical demand zone near $0.6240.

This level had previously initiated several rejections and could attract more buyers in the near future as they look forward to investing in the recent dip as selling pressure cools.

Source: TradingView

Momentum indicators hint at seller exhaustion

Coming in defense of the $0.6240 demand zone, technical indicators also suggest a fading bearish momentum.

VIRTUAL’s Stochastic RSI on the daily chart is in an oversold territory, signaling a fading selling pressure rather than aggressive continuation.

This shift often precedes short-term stabilization, especially near well-defined demand zones.

At the same time, valuation metrics are flashing early recovery signals. The MVRV Z-score sits at 0.321, placing VIRTUAL in an undervalued region.

Historically, such levels have aligned with accumulation phases rather than sustained downtrends.

The current undervalued price presents a buying opportunity for prospective buyers, a positive sentiment that could shift the market dynamics in the current demand zone.

Source: Santiment

Tactical repositioning?

Consequently, the number of withdrawing addresses has reduced significantly recently.

The reduction points to a tactical realignment of investors and long-term holders as they anticipate a further price rally after the potential rally at the current demand zone.

Source: Santiment

Dormant circulation strengthens the accumulation case

That’s not all; VIRTUAL’s dormant circulation has fallen to its lowest level – the 90-day dormant circulation was at 25k at press time.

The older tokens remained largely inactive, reducing the likelihood of sudden sell pressure from long-term holders.

Low dormant circulation typically reinforces accumulation phases, especially during market pullbacks. The same trajectory is coming into play on the Virtual Protocol.

Source: Santiment

What this means for VIRTUAL

Taken together, VIRTUAL’s price reaction at the $0.6240 demand zone, weakening selling momentum, and supportive on-chain metrics all reinforce the likelihood of a near-term reversal.

However, confirmation remains key. VIRTUAL buyers must hold current levels and push price above short-term resistance to confirm a recovery.

Until then, volatility is expected as the market tests whether this correction will be an accumulation or just another pause before bearish continuation.


Final Thoughts

  • VIRTUAL’s drop has pushed its price into a historically strong demand zone near $0.6240.
  • Stochastic RSI and MVRV Z-score suggest selling momentum is fading, raising reversal prospects.
Next: Ethereum slips to $2.2K as ‘extreme fear’ hits – Why THIS level decides next bull run

Source: https://ambcrypto.com/virtual-these-levels-hint-at-a-potential-reversal-ahead/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26